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Inactivation of the von Hippel–Lindau tumour suppressor in renal cell carcinoma (RCC) leads to failure of proteolytic regulation of
the a subunits of hypoxia-inducible factor (HIF), constitutive upregulation of the HIF complex, and overexpression of HIF target
genes. However, recent studies have indicated that in this setting, upregulation of the closely related HIF-a isoforms, HIF-1a and
HIF-2a, have contrasting effects on tumour growth, and activate distinct sets of target genes. To pursue these findings, we sought to
elucidate the mechanisms underlying target gene selectivity for HIF-1a and HIF-2a. Using chromatin immunoprecipitation to probe
binding to hypoxia response elements in vivo, and expression of chimaeric molecules bearing reciprocal domain exchanges between
HIF-1a and HIF-2a molecules, we show that selective activation of HIF-a target gene expression is not dependent on selective DNA-
binding at the target locus, but depends on non-equivalent C-terminal portions of these molecules. Our data indicate that post-DNA
binding mechanisms that are dissimilar for HIF-1a and HIF-2a determine target gene selectivity in RCC cells.
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Hypoxia-inducible factor is a family of a/b heterodimeric DNA-
binding complexes that act as transcriptional master regulators of
the response to low oxygen tensions (Wang et al, 1995). Hypoxia-
inducible factor activity is upregulated in cancer by a variety of
processes including microenvironmental hypoxia, tumour sup-
pressor gene action, growth factor activity and cellular deficiencies
of ascorbate and iron. Increased expression of the regulatory HIF-a
subunits has been associated with tumour aggression and poor
prognosis, leading to interest in defining ways of downregulating
the pathway as a potential therapeutic strategy in cancer (for
review see Harris, 2002; Semenza, 2003).
Hypoxia-inducible factor-a chains are encoded by three
independent loci. All three gene products dimerise with constitu-
tively expressed HIF-b chains, also known as aryl hydrocarbon
receptor nuclear translocators. This heterodimer binds to DNA
and recruits the p300/CBP coactivator proteins to form an active
transcriptional complex. Oxygen-dependent proteolytic regulation
of HIF-a chain stability is achieved via a prolyl hydroxylase (PHD
1-3)/von Hippel–Lindau (VHL) tumour suppressor protein
ubiquitin ligase/proteasome pathway, while coactivator recruit-
ment is controlled by the HIF asparaginyl hydroxylase, factor
inhibiting HIF (FIH) that catalyses hydroxylation of an asparagine
residue in the carboxy-terminal (C-terminal) activation domain,
blocking association with p300/CBP in the presence of oxygen (for
review see Hirota and Semenza, 2005; Schofield and Ratcliffe,
2005).
Hypoxia inducible factor-1a and HIF-2a are the best studied
HIF-a isoforms. They have a highly conserved domain architec-
ture, including sites of prolyl and asparaginyl hydroxylation, and
strongly promote transcription from similar hypoxia response
elements (HREs). However, there is increasing evidence for the
functional non-equivalence of HIF-1a and HIF-2a, and in cancer,
several recent studies have indicated that, at least in certain
settings, they have contrasting effects on tumour growth
(Maranchie et al, 2002; Kondo et al, 2002, 2003; Zimmer et al,
2004; Covello et al, 2005; Raval et al, 2005). In VHL-defective renal
carcinoma cells (RCC), inactivation of HIF-a proteolysis upregu-
lates both HIF-1a and HIF-2a with global induction of HIF target
gene expression (Maxwell et al, 1999), stimulating investigations of
the role of the HIF pathway in tumour development (Maranchie
et al, 2002; Kondo et al, 2002, 2003; Zimmer et al, 2004; Raval et al,
2005). These studies have shown that suppression of HIF-2a
retards and overexpression of HIF-2a enhances the growth of
experimental tumours derived from RCC cells. In contrast,
overexpression of HIF-1a was found to retard the growth of
similar RCC-derived experimental tumours. Interestingly, clinical
RCC shows an unusual bias to greater HIF-2a rather than HIF-1a
expression (Krieg et al, 2000; Turner et al, 2002), and in kidneys
from patients with VHL disease, greater HIF-2a expression is
associated with more advanced lesions (Mandriota et al, 2002).
Taken together, these findings strongly suggest that HIF-2a has
pro-tumorigenic actions in RCC that are isoform specific, and not
shared by HIF-1a. In keeping with this, HIF-1a and HIF-2a show
clear transcriptional selectivity, with studies to date defining at
least two types of isoform-specific responses; certain genes appear
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sexclusively responsive to HIF-1a in both RCC and non-RCC cells,
whereas others respond to both HIF-1a and HIF-2a in non-RCC
cells, and are dominantly regulated by HIF-2a in RCC cells (Hu
et al, 2003; Sowter et al, 2003; Raval et al, 2005). Hence, RCC cells
display marked HIF-a chain selectivity in target gene responses
that likely underlie differences in the role of these molecules in
promoting tumour growth. Clearly, if the HIF pathway is to be
optimally targeted for cancer therapy, it will be important to
understand the basis of these differences.
In the current work, we therefore sought to analyse mechanisms
underlying selective activation by HIF-1a and HIF-2a, and
demonstrate that selectivity is not a function of differential
binding of HIF-1a and HIF-2a to regulatory HREs, but involves
post-DNA-binding mechanisms mediated by more C-terminal
regions of the HIF-a proteins that are distinct for each HIF-a
isoform.
MATERIALS AND METHODS
Plasmid construction
To generate chimaeric HIF-a expression plasmids, site-directed
mutagenesis was performed on pcDNA, Hs.HIF-1a and pcDNA.
Hs.HIF-2a (Cockman et al, 2000) to introduce novel restriction
sites without changing the encoded protein using primers listed in
Supplementary Table 1. After confirmation by restriction digestion
and DNA sequencing, the sites introduced were used to allow
domain exchange by standard recombinant techniques. These
chimaeric HIF-a sequences were transferred into the retroviral
vector pLZRS-IRES-GFP (Jacobs et al, 1999). Retroviral production
and infection of target cells were conducted as previously
described (Raval et al, 2005).
A 1.1kb fragment of the PHD3 first intron (14328421 to
14327303, antisense strand, NT_026437.10) and a 1kb fragment of
the PHD3 promoter upstream to the translation start site
(33490609 to 33489711, antisense strand, NC_000014.7) were
amplified by PCR from human genomic DNA using primers
containing the appropriate restriction sites (Sigma Genosys, UK).
Primers for the former were 50-ATggtacc(KpnI)TTGATTGG
TAACTTCG 30- and 50-ACG aga tct(BglII) ATA GTT CTA CCA
GGC 30. Primers for the latter were 50-ACT aga tct(BglII) TCT TCA
TTG TGC TCA TCC CC 30 and 50 CGc cat gg(NcoI)T CGC CCG
CAG AAT CGA GGT CC-30. PHD3.HRE-SV40-luc was created by
cloning the PHD3 first intron fragment into the multiple cloning
site of pGL3promoter (Promega, Southampton, Promega, UK). A
mutant HRE version of this reporter was created using site-
directed mutagenesis with: 50-CCACCCTCACGCAGCGacat
TAGCCCTGTCACTCAGCC-30 and a complementary oligonucleo-
tide 50 GGC TGA GTG ACA GGG CTA atg tCG CTG CGT GAG GGT
GG 30 (mutated nucleotides in lower case). Replacement of the
SV40 promoter in pGL3promoter with the cloned PHD3 promoter
gave rise to PHD3.HRE-PHD3pro-luc. PHD3pro-luc-PHD3.HRE
was created by placing the PHD3 first intron fragment into a
BamHI site downstream of the poly(A) signal in pGL3promoter
using the following primers: 50-Ggg atc c(BamHI)TC GAG TTG
ATT GGT AAC TTC G-30 and 50-Ggg atc c(BamHI)AT AGT TCT
ACC AGG C-30. pCMV-b-galactosidase (O’Rourke et al, 1999),
CA9pro.HRE-luc (p506), p173 and p36 (Wykoff et al, 2000) have
been described previously.
Cell culture
The VHL competent cell lines used were Caki-1 (spontaneous renal
carcinoma; originally from ECACC). Hep 3B (hepatoma containing
integrated hepatitis B viral genome; originally from ECACC) and
MCF-7 (metastatic mammary adenocarcinoma; originally from
ECACC). The VHL defective cell lines 786-O (originally from
ATCC), A498 (originally from ECACC) and RCC4 (a gift from
CHMC Buys) were all derived from renal clear cell tumours. All cell
lines were maintained in Dulbecco’s modified Eagles Medium
supplemented with 10% fetal calf serum, 2mML -glutamine, 50IU/
ml penicillin and 50mg/ml streptomycin. Stable transfectants of
RCC4 containing HRE-linked reporter genes were selected and
maintained in 1mg/ml puromycin. Cells were grown in either
normoxia (21% oxygen and 5% carbon dioxide) or hypoxia (1%
oxygen and 5% carbon dioxide for 16h) in an Invivo2 hypoxic
workstation (Ruskinn Technologies, Bridgend, UK).
Transient transfections
Two sets of siRNA duplexes targeting HIF-1a and HIF-2a were
used as described previously (Sowter et al, 2003; Warnecke et al,
2004). The scrambled siRNA duplexes and those targeting
Drosophila melanogaster HIF-1a were used as controls. For
reporter assays, cells were plated at 30% density in 12-well plates
in antibiotic-free medium on day 0. In siRNA suppression
experiments, cells were transfected with siRNA duplexes (20–
100nM) using Oligofectamine reagent (Invitrogen, Paisley, UK) on
day 1, cotransfected with siRNA duplexes (20–100nM), 800ng
luciferase reporter plasmid and 200ng pCMV-b-galactosidase
plasmid using Lipofectamine 2000 Reagent (Invitrogen) on day
2, and harvested on day 3. In overexpression experiments, cells
were cotransfected with 500ng HIF-a expression plasmid
(pcDNA.Hs.HIF-1a or pcDNA.Hs.HIF-2a), 300ng HRE-linked
luciferase reporter plasmid (PHD3.HRE-PHD3pro-luc, PHD3pro-
luc-PHD3.HRE or CA9pro.HRE-luc) and 200ng pCMV-b-galacto-
sidase plasmid using Lipofectamine 2000 reagent on day 1, and
harvested on day 2.
Cells were collected in 100ml1  passive lysis buffer (Promega)
and assayed for luciferase activity according to the manufacturer’s
instructions. b-Galactosidase assay was performed to normalise for
transfection efficiency.
Immunoblotting
Whole cell extracts from six-well plates were prepared in urea-
sodium dodecyl sulphate (SDS) buffer, normalised for total protein
content, resolved and transferred as previously described (Raval
et al, 2005). Primary antibodies were mouse monoclonal
antibodies against HIF-1a (clone 54, Transduction Laboratories,
Oxford, UK), HIF-2a (NB-100 132, Novus Biologicals, Littleton,
CO, USA), CA9 (M75) (Pastorekova et al, 1992), PHD3 (188e)
(Appelhoff et al, 2004) and b-tubulin (clone 2-28-33, Sigma,
Gillingham, UK). Horseradish peroxidase-conjugated goat anti-
mouse secondary antibody (DAKO, Ely, UK) and ECL Plus system
(Amersham Biosciences, Little Chalfont, UK) were used for
detection.
Chromatin immunoprecipitation
Cells were grown in 150-mm dishes to about 80% confluency
before being subjected to formaldehyde crosslink, harvest and
chromatin immunoprecipitation (chIP) using standard ChIP
protocols (Wells and Farnham, 2002; Weinmann and Farnham,
2002). Hep3B cells were treated with desferrioxamine at a final
concentration of 100mM for 16h before formaldehyde crosslink.
The rabbit polyclonal anti-HIF-1a (PM14) and anti-HIF-2a (PM9)
antibodies were used in the IP. PM14 and PM9 were raised by
immunising a rabbit with a fusion protein consisting of
glutathione- S-transferase fused to amino acids 445–553 of mouse
HIF-1a or amino acids 357–439 of mouse HIF-2a, respectively.
Both antisera cross react with the relevant human HIF isoforms.
Dilution buffer and rabbit immunoglobulin were used as negative
controls. The resulting DNA was analysed by PCR with primers
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(Supplementary Table 1).
For ChIP–Western analysis, urea–SDS lysis buffer was added
directly onto the beads used for IP of DNA–protein complexes
after the washing steps and boiled at 951C for 5min. After
centrifugation at 4000r.p.m. for 5min, the supernatant was
separated by polyacrylamide gel electrophoresis, transferred and
blotted with mouse monoclonal antibodies against HIF-1a and
HIF-2a.
RESULTS
Previous work with non-RCC cells has indicated that although the
large majority of hypoxia inducible genes are responsive to HIF-1a
(Hu et al, 2003; Park et al, 2003; Sowter et al, 2003; Manalo et al,
2005; Wang et al, 2005), two distinct patterns of response are
observed with some genes being exclusively responsive to HIF-1a
and some responding to both HIF-1a and HIF-2a. In RCC cells,
this transcriptional selectivity is more marked with the former
group of genes remaining exclusively responsive to HIF-1a and
the latter becoming dominantly, or even exclusively, responsive
to HIF-2a (Sowter et al, 2003; Raval et al, 2005). To simplify the
analysis of mechanisms underlying these patterns of transcrip-
tional selectivity, we selected two genes, CA9 and PHD3, that
manifest particularly strong hypoxia-inducible responses from low
basal levels of expression in normoxic non-RCC (VHL competent)
cells. CA9 has previously been reported to be induced by HIF-1a
alone in all cell types (Grabmaier et al, 2004; Raval et al, 2005),
whereas PHD3 had been demonstrated to be regulated by both
HIF-1a and HIF-2a in non-RCC cells, but had not been studied in
this way in RCC cells (Aprelikova et al, 2004). First, we showed the
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Figure 1 Regulation of PHD3 by HIF-1a and HIF-2a in renal cell carcinoma (RCC) and non-RCC lines. (A) and (B) Representative western blots showing
HIF-1a, HIF-2a, CA9, PHD3 and b-tubulin protein levels in whole cell lysates of Hep3B and RCC4 cells under conditions of normoxia (N) or hypoxia (H)
following siRNA suppression with a control sequence (C) or sequences targeting HIF-1a (H1), HIF-2a (H2), using siRNA duplexes as described by
Warnecke et al, 2004. (C) and (E) Representative western blots showing HIF-1a, HIF-2a, PHD3 and b-tubulin protein levels in whole cell lysates of VHL-
competent RCC and non-RCC lines (C) and VHL-defective RCC lines (E) following siRNA suppression with a control sequence (C) or sequences targeting
HIF-1a (H1), HIF-2a (H2) or both (H1þ2), using siRNA duplexes as described by Sowter et al, 2003, under conditions of normoxia (N) or hypoxia (H).
(D) and (F) Quantitation of changes in PHD3 protein levels, measured by densitometry, from at least three independent repetitions of this experiment
(error bars corresponding to one standard deviation). In the VHL competent cell lines both HIF-1a and HIF-2a influence PHD3 levels whereas in the
VHL-defective cells the effects of HIF-2a are predominant.
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scontrasting behaviour in response to HIF-1a and HIF-2a siRNA of
CA9 and PHD3 in Hep3B and RCC4 cells (Figure 1, panels A and
B), using siRNA duplexes as described in Warnecke et al (2004).
As expected, CA9 expression was dominantly affected by HIF-1a
siRNA in both cell types. In contrast, PHD3 expression was
modulated by both HIF-1a and HIF-2a siRNA in Hep3B cells, but
predominantly by HIF-2a siRNA in RCC4 cells. To examine the
generality of these effects, we compared the effects of siRNA-
mediated suppression of HIF-1a or HIF-2a on PHD3 expression in
a wider selection of RCC and non-RCC cells, using the independent
HIF isoform-specific siRNA duplexes described by Sowter et al
(2003). These experiments confirmed striking induction by
hypoxia, and dependence of this response on both HIF-1a and
HIF-2a in non-RCC cells (Figure 1, panels C and D). In contrast, in
RCC cells, PHD3 expression was dominantly dependent on HIF-2a
(Figure 1, panels E and F) whether the cells expressed
electrophoretically normal HIF-1a (RCC4), HIF-1a protein with
enhanced electrophoretic mobility (A498) or no immunoreactive
HIF-1a protein (786-0). The concordance of results produced with
independent sets of siRNA duplexes indicates that they are due to
specific effects on the targeted isoform. Thus, PHD3 expression
conforms to the pattern that has previously been described for HIF
target genes such as VEGF and GLUT1 (Raval et al, 2005), and
indicating that PHD3 would be a suitable gene to study HIF-2a-
dependent selectivity in RCC cells.
At the time we initiated this work, the location of the hypoxia
response element necessary for hypoxic induction of PHD3
expression was unknown. Our in silico analysis revealed a
consensus HRE in the mid-part of the first intron of the PHD3
gene, which is conserved between mouse and human genomes
(Figure 2A). To test the function of this sequence experimentally,
we inserted a 1.1kb genomic fragment containing the putative
HRE into pGL3promoter adjacent to a SV40 promoter. Following
transient transfection into Hep3B cells, the wild-type sequence, but
not a variant containing a mutation in the HRE core motif,
conferred hypoxic upregulation of luciferase activity (Figure 2B).
The HRE thus defined is in keeping with that identified in recently
published data (Pescador et al, 2005).
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Figure 2 Definition of a hypoxia response element (HRE) within intron
1 of PHD3. (A) Alignment of human and mouse sequences showing
putative HRE within intron 1 of PHD3 (numbers represent nucleotides of
human PHD3 first intron, NT_026437.10). The box outlines a consensus
HRE sequence on the antisense strand. (B) Luciferase activity (RLU) of
whole cell lysates from Hep3B cells transfected with either lipofectamine
alone, wild-type PHD3 HRE-linked reporter or mutant PHD3 HRE-linked
reporter (ACGTG mutated to AATGT) under conditions of normoxia (N)
or hypoxia (H), corrected for transfection efficiency. Values are the mean of
three independent repeats and error bars correspond to one standard
deviation. The wild-type, but not mutant, HRE sequence confers hypoxia
inducible expression of luciferase.
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Figure 3 HIF-a occupancy of target gene hypoxia response elements (HREs) identified by chromatin immunoprecipitation (ChIP) in RCC and non-RCC
lines. (A–C) ChIP material obtained using rabbit polyclonal antibodies against HIF-1a (anti HIF-1a) or HIF-2a (anti HIF-2a) was analysed with PCR primers
that amplify either the CA9 or PHD3 HRE in RCC4 (A), 786-O (B) and Hep3B (C) cells under conditions of normoxia (N) or treatment with 100mM
desferrioxamine for 16h (Df). Controls include reactions using the unfractionated cross-linked DNA-protein complexes (input) and following ChIP without
primary antibody (no Ab) and or with normal rabbit immunoglobulin (rabbit Ig). Chromatin immunoprecipitation resulted in selective enrichment of DNA
fragments containing CA9 or PHD3 HREs by both HIF-1a and HIF-2a suggesting that HIF-a transcriptional selectivity is not due to DNA binding selectivity.
(D) Immunoblots detecting HIF-1a (upper panel) or HIF-2a (lower panel) of chromatin immunoprecipitated material from RCC4 using antibodies against
HIF-1a, HIF-2a or without primary antibody (no Ab) compared with unfractionated cross-linked DNA-protein complexes (input), confirming the specificity
of the anti-HIF-a rabbit polyclonal antibodies used. Whole cell lysates of 786-O cells retrovirally overexpressing HIF-1a (786-OþpLZRS HIF-1a) or HIF-2a
(786-OþpLZRS HIF-2a) were used as controls for the western blot. (Note that the HIF-a detected following ChIP migrated more slowly than the control
HIF-a due to cross-linked DNA.).
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by HIF-a isoforms could explain the observed transcriptional
selectivity for HIF-1a versus HIF-2a, we performed chIP studies
using rabbit polyclonal antibodies against HIF-1a and HIF-2a and
PCR primers that amplify either the CA9 or PHD3 HRE. Analysis
of the immunoprecipitates from RCC4 cells revealed capture of
both CA9 and PHD3 HREs with both HIF-1a and HIF-2a
antibodies (Figure 3A), despite contrasting activation by HIF-1a
(CA9) or HIF-2a (PHD3). Further analysis of immunoprecipitates
from 786-O cells revealed enrichment of both HREs by the
antibody to HIF-2a, but as expected neither HRE was captured in
immunoprecipitates using the antibody against HIF-1a
(Figure 3B), as immunodetectable HIF-1a is not present in this
cell line. The capture of the CA9 HRE by the antibody to HIF-2a
in 786-O cells again contrasts with the observed pattern of
transcriptional activation, as these cells normally do not express
detectable levels of CA9 protein even in the presence of high levels
of HIF-2a protein. To investigate whether these phenomena were
specific to VHL-defective RCC cells, we examined the occupancy
of HREs by HIF-a isoforms in Hep3B cells, with and without HIF
induction following treatment with desferrioxamine. Again,
capture of both PHD3 and CA9 HREs was seen with both HIF-1a
and HIF-2a IP (Figure 3C). To exclude the possibility that these
results arose from cross-reactivity of the polyclonal anti-HIF-1a
and anti-HIF-2a antisera, we confirmed specificity by analysing the
immunoprecipitates from RCC4 cells directly by immunoblotting
with independent isoform-specific monoclonal antibodies against
HIF-1a and HIF-2a (Figure 3D). The results indicate that both HIF-
a isoforms bind in vivo to the HREs of target genes predominantly
activated by one isoform alone, suggesting that HIF-a target gene
selectivity in VHL-defective RCC and other cell types is not due to
selective DNA binding.
To analyse the domains within the HIF-a isoform proteins
responsible for selectivity, we next analysed the ability of a series
of chimaeric HIF-a proteins, bearing reciprocal exchanges of
major domains between HIF-1a and HIF-2a (Figure 4A), to
activate CA9 and PHD3 in 786-O cells. Retroviral expression of
full-length HIF-1a but not HIF-2a restored expression of CA9 in
786-O cells. Transfer of the HIF-1a basic-loop–helix domain
(amino acids 1–95) implicated in DNA binding into the HIF-2a
molecule did not enable activation of the CA9 gene. In contrast,
replacement of the entire C-terminal HIF-2a sequence (amino
acids 95–870) with the equivalent HIF-1a sequence (amino acids
96–826) was sufficient to convey full activity on the CA9 target
gene. Comparison of the effects of the chimaera containing HIF-1a
amino acids 96–826 with those containing less extensive C-
terminal sequences (Figure 4B; lanes 8–11) showed a marked loss
of activity as the HIF-1a sequence was reduced to amino acids
390–826, thus implicating HIF-1a amino acids 96–390 as
necessary for expression of CA9. However, consideration of a
further series of chimaeras containing progressive extensions of
the HIF-1a N-terminal sequences (Figure 4B; lanes 4–7) indicated
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Figure 4 Use of chimaeric HIF-a to define HIF-a domains determining transcriptional selectivity in 786-O cells. (A) Schematic diagram of HIF-a chimaeras
created in the retroviral expression vector pLZRS-IRES-GFP. Numbers indicate amino acid residues of the N- and C-terminal portions of HIF-1a and HIF-2a
in these chimaeric molecules. Double lines indicate position of epitopes recognised by the anti-HIF-a monoclonal antibodies used. (B) Representative
immunoblots detecting HIF-1a, HIF-2a, PHD3 and CA9 proteins in whole cell lysates of 786-O cells after retroviral infection with viruses expressing no
protein (vector alone), wild-type HIF-1a (HIF-1a 1-826), wild-type HIF-2a (HIF-2a 1-870) and the indicated chimaeric HIF-a molecules. Transcriptional
selectivity is not determined by HIF-a domains involved in DNA binding, but through non-congruent C-terminal portions of these molecules.
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expression. Indeed, induction of CA9 expression by a chimaera
containing HIF-1a amino acids 1–574 but not by a chimaera
containing HIF-1a amino acids 1–411 indicated that residues
between 411 and 574 are also necessary for this response
(Figure 4B).
Analysis of PHD3 indicated that in contrast with CA9, but in
keeping with results of the siRNA-mediated suppression experi-
ments, PHD3 expression was enhanced by retroviral expression of
full-length HIF-2a but not by HIF-1a. Again, transfer of the HIF-2a
basic-helix–loop–helix domain (amino acids 1–94) implicated in
DNA binding into the HIF-1a molecule did not enable activation of
the PHD3 gene, whereas replacement of the entire C-terminal
HIF-1a sequence with the equivalent HIF-2a sequence (amino
acids 95–870) was sufficient to convey full activity on the PHD3
target gene. So far the relationship between HIF-1a and CA9 and
that between HIF-2a and PHD3 appeared to be reciprocal.
However, further analysis revealed that whereas extension of the
N-terminal HIF-2a sequence to amino acids 1–542 did not restore
PHD3 activation to the chimaera, the HIF-2a C-terminal sequences
543–870 conveyed full activity, indicating that these sequences
were both necessary and sufficient for HIF-2a activation of PHD3
(Figure 4B).
Thus in keeping with the chIP experiments that indicated
equivalent DNA binding of HIF-1a and HIF-2a, transcriptional
selectivity was not determined by domains involved in DNA
binding but by C-terminal sequences. Interestingly, however, the
C-terminal sequences responsible for activation of CA9 or PHD3
were not congruent between the HIF-a isoforms, with more
extensive sequences being required for the activation of CA9 by
HIF-1a sequences. These results are in keeping with a role for the
HIF-1a N-terminal activation domain in the specific activation of
the CA9 gene and the HIF-2a C-terminal activation domain in
activating the PHD3 gene in RCC. However, the chimaeric protein
analysis indicates that the HIF-1a sequence requirements for CA9
activation are more extensive than the minimal N-TAD, with
amino acids 96–390 and 411–574, both being necessary for the
response. Note that these experiments do not formally distinguish
between activation by C-terminal sequences or repression by the
N-terminal sequences, although given existing data mapping
activation domains to the C-terminal portions of these molecules
(Jiang et al, 1996; O’Rourke et al, 1999), the former is more
probable. These data imply that interactions between the defined
domains and one or more proteins are necessary to achieve
transcriptional selectivity, presumably resulting from interaction
with DNA sequences other than the minimal HRE at the relevant
gene locus. This led us to explore the cis-acting determinants that
might be responsible for transcriptional selectivity at the CA9 and
PHD3 loci.
We first compared the HIF-a isoform dependence of the activity
of PHD3.HRE-PHD3pro-luc, containing the PHD3 intronic en-
hancer as a 1.1kb fragment and the PHD3 promoter in
pGL3promoter with that of a 506bp fragment encompassing the
human CA9 promoter. DNA sequences were transiently transfected
into either Hep3B cells or RCC4 cells that had been pre-exposed to
siRNAs directed against HIF-1a and/or HIF-2a so as to achieve
specific suppression of one or both HIF-a isoforms. Results are
summarised in Figure 5 (panels A and B). The DNA sequences
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Figure 5 Analysis of cis-acting determinants of HIF-a transcriptional selectivity through transient transfection of luciferase reporter plasmids containing
PHD3 enhancer or CA9 promoter sequences. (A) and (B) Luciferase activity (RLU) of whole cell lysates of Hep3B (A) or fold change in RLU of whole cell
lysates in RCC4 (B) cells transiently transfected with luciferase reporter plasmids driven by the PHD3 enhancer and promoter (PHD3.HRE-PHD3pro-luc)
or the CA9 promoter (CA9 pro.HRE-luc) following siRNA suppression with a control sequence (C) or sequences targeting HIF-1a (H1), HIF-2a (H2) or
both (H1þ2) under conditions of normoxia (N) or hypoxia (H), corrected for transfection efficiency. Experiments with RCC4 cells were conducted in
normoxia. Expression of both reporter plasmids is reduced when HIF-1a is suppressed but not when HIF-2a alone is suppressed. (C) and (D) Luciferase
activity (RLU) of whole cell lysates of Hep3B cells (C) or fold change in RLU of whole cell lysates in RCC4 (D) cells transiently co-transfected with luciferase
reporter plasmids driven by the PHD3 enhancer and promoter (PHD3.HRE-PHD3pro-luc) or the CA9 promoter (CA9 pro.HRE-luc) and vectors
expressing no protein (pcDNA3) or the indicated HIF-a isoforms under conditions of normoxia (N) or hypoxia (H), corrected for transfection efficiency.
Experiments with RCC4 cells were conducted in normoxia. Expression of the reporter plasmid driven by the PHD3 enhancer and promoter (PHD3.HRE-
PHD3pro-luc) is influenced to a greater extent by HIF-2a over-expression than HIF-1a over-expression, whereas expression of the reporter plasmid driven
by the CA9 promoter is influenced to a greater extent by HIF-1a over-expression than HIF-2a over-expression. Panels (A) and (C) are representative
histograms. Values in panels (B) and (D) are mean of three independent experiments, error bars indicate one standard deviation.
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induction by HIF-1a siRNA alone was more effective for CA9
than for PHD3, in both Hep3B cells and RCC4 cells. Surprisingly,
however, the most striking finding was that the dominant
dependence of HIF-2a expression observed for endogenous
PHD3 expression in RCC4 cells was not observed for the PHD3
enhancer linked reporter gene expression. Rather, the PHD3
reporter gene expression was most effectively suppressed by
siRNA directed against HIF-1a.
One potential explanation for the dominant activity of HIF-1a
siRNA on the 1.1kb PHD3 intronic enhancer and the 506bp CA9
promoter is that these elements are simply incapable of responding
to HIF-2a at all. To test this possibility, we cotranfected these
reporters with plasmids expressing either HIF-1a or HIF-2a in
both Hep3B and RCC4 cells. Results shown in Figure 5 (panels C
and D) reveal striking activation of the PHD3 intronic enhancer by
HIF-2a that greatly exceeded that observed with HIF-1a. The CA9
promoter also responded to HIF-2a, but less well than the PHD3
intronic enhancer.
We did not measure the overall levels of HIF-1a and HIF-2a
achieved in the transiently transfected cell populations. However, it
is noteworthy that the levels of HIF-1a and HIF-2a produced by
overexpression had contrasting relative effects on the two reporters,
with HIF-1a being more active than HIF-2a on the CA9 reporter and
HIF-2a was more active than HIF-1a on the PHD3 reporter,
suggesting that the results did not simply arise because one, or the
other, isoform was more heavily overexpressed.
Taken together, these findings indicate that at least a proportion
of the selectivity of the endogenous CA9 gene for HIF-1a is
conveyed by transiently transfected promoter sequences, but that
the selectivity of endogenous PHD3 for HIF-2a is not conveyed by
a PHD3 promoter/enhancer sequence, at least as configured in
PHD3.HRE-PHD3pro-luc, even though this sequence is strikingly
responsive to overexpressed HIF-2a.
To analyse further sequences conveying HIF-1a selectivity at the
CA9 promoter, we tested the activity of a series of CA9 promoter
deletions by transient transfection of Hep3B cells that had been
pretreated with siRNAs directed against HIF-1a and/or HIF-2a as
outlined above. Results are shown in Figure 6A, revealing that all
are dominantly responsive to HIF-1a, and that the minimal (36bp)
promoter appears exclusively responsive to HIF-1a.
In further experiments we sought to analyse mechanisms that
might underlie the difference between effects of HIF-2a on the
endogenous PHD3 gene and effects on the juxtaposed enhancer/
promoter sequence in PHD3.HRE-PHD3pro-luc. We considered
whether altering spacing between the promoter and enhancer
might affect HIF-a selectivity. The PHD3 enhancer was therefore
moved to a more distant position 30 to the luciferase reporter gene
in PHD3pro-luc-PHD3.HRE. Analysis of activity in transiently
transfected RCC4 cells again showed that activity was dominantly
mediated by HIF-1a rather than HIF-2a (Figure 6B). We therefore
considered the possibility that stable integration into chromatin
might be required for selective responses to HIF-2a. To address
this, we selected stable transfectants of RCC4 cells expressing
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Figure 6 A minimal promoter is sufficient to confer HIF-a selectivity in CA9 while additional determinants are required for PHD3. (A) Luciferase activity
(RLU) of whole cell lysates from Hep3B cells transiently transfected with a series of luciferase reporters containing CA9 promoter sequences containing the
indicated number of nucleotides (p506, p173 and p36) following control treatment with lipofectamine alone (lipofectamine) or siRNA suppression with
sequences targeting HIF-1a (H1), HIF-2a (H2) or both (H1þ2) under conditions of normoxia (N) or hypoxia (H). (B) Fold changes in RLU of whole cell
lysates from RCC4 cells transiently transfected with luciferase reporter plasmids driven by the PHD3 enhancer adjacent to the PHD3 promoter
(PHD3.HRE-PHD3pro-luc) or driven by the PHD3 enhancer positioned downstream of the PHD3 promoter and luciferase sequence (PHD3pro-luc-
PHD3.HRE) following siRNA suppression with sequences targeting HIF-1a (H1), HIF-2a (H2) or both (H1þ2) compared with a control sequence (C) in
normoxia. In both panels (A) and (B), values are the mean of three independent experiments, error bars correspond to one standard deviation. (C) Fold
change in RLU in a representative RCC4 clone following stable transfection with a luciferase reporter plasmid driven by the PHD3 enhancer positioned
downstream of the PHD3 promoter and luciferase sequences PHD3pro-luc-PHD3.HRE following siRNA suppression with sequences targeting HIF-1a (H1),
HIF-2a (H2) or both (H1þ2) compared with a control sequence (C) in normoxia. Luciferase activity was normalised with total protein content. Similar
results were obtained using an independent stable clone bearing the same plasmid.
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sPHD3pro-luc-PHD3.HRE. However, the activity of the PHD3
enhancer/promoter reporter gene was again suppressed by siRNA
directed against HIF-1a but not HIF-2a (Figure 6C).
DISCUSSION
Inactivation of the pVHL tumour suppressor is observed in the
majority of inherited and sporadic RCC leading to constitutive
stabilization of both HIF-1a and HIF-2a and constitutive
upregulation of HIF target gene expression (Kaelin, 2002).
However, recent studies have revealed that in this setting,
upregulation of HIF-1a and HIF-2a activates distinct target genes
and has contrasting effects on the growth of tumours (Maranchie
et al, 2002; Kondo et al, 2002, 2003; Zimmer et al, 2004; Raval et al,
2005). These findings imply that strategies for therapeutic
blockade of HIF pathways for RCC should most likely attempt to
be isoform specific. In this work, we therefore sought to analyse
the mechanisms underlying target gene selectivity for HIF-1a
versus HIF-2a in RCC. We performed a detailed analysis of two
genes displaying highly contrasting HIF-a isoform-specific regula-
tion that is typical of previously analysed patterns of response for
two distinct groups of genes. The gene encoding CA9 conforms to
a pattern first described among genes encoding glycolytic enzymes
(Hu et al, 2003), and is specifically responsive to HIF-1a, showing
no response to HIF-2a in any cell type, whether non-RCC or RCC
(Grabmaier et al, 2004; Raval et al, 2005). The gene encoding PHD3
conforms to a pattern previously reported for genes encoding a
variety of proteins including VEGF and GLUT1 (Raval et al, 2005);
it responds dominantly or exclusively to HIF-2a in RCC cells, but
to both HIF-1a and HIF-2a in non-RCC cells.
Our findings indicate that this target gene selectivity is achieved
by post-DNA-binding mechanisms. Chromatin immunoprecipita-
tion experiments demonstrated non-selective binding for HIF-1a
versus HIF-2a at functional HREs for genes that are selectively
responsive to these transcription factors. Furthermore, domain
exchange experiments indicated that the ability to activate a target
gene was not conferred by exchange of the basic-helix–loop–helix
sequences previously implicated in DNA-binding (Jiang et al,
1996). Interestingly, despite the ability of transcription factors to
bind at sites where they were not transcriptionally active (e.g.
HIF-2a at the CA9 promoter), siRNA suppression of the inactive
isoform did not clearly enhance transcription, suggesting that
competition for binding is not important at endogenous levels of
the proteins, at least under the circumstances examined.
Further analysis suggested that the post-DNA binding mecha-
nisms activating target gene expression are different for the HIF-1a
target CA9 and the HIF-2a target PHD3. First, the results of the
HIF-1a/HIF-2a domain exchange experiments were non-reciprocal,
and implicated non-equivalent sequences in activation of CA9 and
PHD3 expression. Second, experiments directed towards defining
the cis-acting DNA sequences at the CA9 and PHD3 loci that might
mediate HIF-a isoform-selective responses yielded quite different
results. Thus, for CA9, these experiments suggested that sequences
at the minimal promoter could convey selective responses to HIF-
1a. siRNA-mediated suppression of HIF-a isoforms indicated that
the minimal CA9 promoter, like the endogenous gene, was
specifically responsive to endogenous HIF-1a and not HIF-2a.
Although some breakdown in selectivity was observed under
conditions of overexpression by transient transfection, in compar-
ison with other HREs, the CA9 promoter again appeared
specifically responsive to HIF-1a, suggesting that specificity
determining sequences in HIF-1a operate through direct or indirect
interactions with factors binding the CA9 promoter.
In contrast, there was no evidence at all of selective activation of
the transfected PHD3 HRE by endogenous HIF-2a. Rather siRNA
suppression experiments revealed that the sequence was dom-
inantly responsive to HIF-1a. This was observed irrespective of
whether the PHD3 HRE was linked to the PHD3 promoter or a
heterologous promoter, for different promoter/HRE spacings, and
in both transiently and stably transfected RCC4 cells. Interestingly,
in contrast with the lack of effect of siRNA-mediated suppression
of HIF-2a, overexpressed HIF-2a powerfully activated the PHD3
HRE. This unexpected finding has recently been noted by others
who have proposed that HIF-2a transcriptional activity is down-
regulated by a titratable repressor that is overcome by over-
expression of the molecule (Hu et al, 2006). Irrespective of this,
our results indicate that despite binding of HIF-2a to the native
PHD3 HRE in the first intron, there is a marked difference between
the activity of HIF-2a in promoting transcriptional activity
mediated by this sequence, and its activity in promoting
expression of the native gene. It is therefore possible that
transcriptional activity of HIF-2a on the native gene is dependent
on ****some aspect of this enhancer/promoter configuration, such
as spacing that is not accurately reproduced in these experiments,
that it is mediated by interaction at other DNA sequences, or that it
involves post-transcriptional mechanisms.
Also of interest is the marked shift to dependence on HIF-2a in
RCC versus non-RCC cells that was observed in these studies for
PHD3, and has been previously observed for genes such as VEGF
and GLUT1 (Sowter et al, 2003; Raval et al, 2005). Although this
might simply reflect greater abundance of HIF-2a versus HIF-1a in
RCC versus non-RCC cells (Maxwell et al, 1999; Krieg et al, 2000),
or, as illustrated here, the presence of abnormal forms of HIF-1a
protein in some RCC, there appeared to be a disproportion, for
instance between modestly greater HIF-2a/HIF-1a protein levels
in RCC4 versus Hep3B cells, and more striking differences in
dependence of PHD3 on HIF-2a. This could reflect the existence of
mechanisms that restrict the activity of HIF-1a or enhance the
activity of HIF-2a in the RCC context. Though our findings do not
distinguish these possibilities, they do indicate that HIF-1a is fully
active in RCC4 cells in directing transcription from the transfected
PHD3 HRE, as in other cell types.
A number of other recent studies have addressed possible
mechanisms underlying differential activity of HIF-1a versus
HIF-2a by different approaches. Though an oxidation susceptible
cysteine residue in the DNA binding domain of HIF-2a has been
proposed to mediate differential activity of HIF-2a versus HIF-1a
(Lando et al, 2000), it is unlikely that this could account for the
post-DNA binding effects we have identified in the current work.
More interestingly, the regulatory subunit of IkB kinase (IKK),
NF-kB essential modulator (NEMO) has been identified as a HIF-
2a binding partner that promotes transcriptional activity (Bracken
et al, 2005). To date however we have not identified any differences
in the levels of NEMO in RCC versus non-RCC cells. Whether more
subtle changes in NEMO activity exist in RCC cells, and more
general analysis of the mode of interaction of HIF-2a with its
endogenous target genes in RCC will require further investigation.
Our studies provide a new focus for such investigations and
indicate that they should be directed at post-DNA-binding
mechanisms regulating HIF-2a target gene expression.
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